Attivare Therapeutics is a pre-clinical biotechnology company developing personalized cancer immunotherapy. ATTImmune delivers intratumoral immune agonists via a biomaterial scaffold; ATT-AI uses single-cell transcriptomics to select patient-specific drug combinations. Programs in AML, solid tumors, and infectious disease.